Wells Fargo lowered the firm’s price target on Halozyme (HALO) to $57 from $62 and keeps an Equal Weight rating on the shares. The firm said on ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full year 2024 financial guidance and raising full year 2025 and multi-year ...

Shares of Halozyme Therapeutics, Inc. HALO were up 5% on Jan. 8 after the company raised its guidance for 2025. The stock gained another 1.8% in after-hours trading. HALO also maintained its full-year ...

The company's strategic focus on expanding its ENHANZE technology and securing key partnerships has been pivotal in driving growth. Halozyme's success in the subcutaneous drug delivery market, coupled ...

Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...

"Halozyme is at the forefront of drug delivery innovation, fostering a high-growth and durable business underpinned by our proprietary ENHANZE drug delivery technology. This leadership position is ...

Halozyme Therapeutics, Inc.'s subcu drug delivery business, driven by ENHANZE technology, shows strong revenue growth with significant collaborations, but faces potential challenges post-2030 due ...

The two rivaling PD-1/L1 drugs both incorporate Halozyme’s recombinant human hyaluronidase-based subcutaneous drug delivery technology, ENHANZE. After delay, Roche's Tecentriq Hybreza wins first ...

1 "We are pleased Opdivo Qvantig, which is co-formulated with our Enhanze drug delivery technology, is now FDA-approved as the first and only subcutaneously administered PD-1 inhibitor in the US ...